Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Denmark / NCT05574673
Recruiting Observational

Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype

NCT05574673 · tracked via the Priya Life Science Denmark tracker
Sponsor
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Phase
Observational
Started
2022-12-01
Last updated
2026-02-27

Condition(s) studied

Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer

Investigational drug(s) / intervention(s)

Standard of care

Standard of care: Patients receive standard of care treatment according to local and national guidelines

Study summary

This is a prospective observational multi-country, multi-center study of a large real-world cohort of first line (1L) epithelial ovarian cancer patients, exposed to standard of care (SOC) treatment stratified according to BRCA1/2 and HRD status.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
100 Years
Healthy volunteers
No
Patients are eligible to be included in the study, if all the following inclusion criteria are met: * Patients with newly diagnosed histologically confirmed epithelial ovarian cancer: * FIGO stage I-II with a known BRCA1/2 mutation (germline/gBRCA or somatic/tBRCA) * FIGO stage III-IV of any histology * Women aged ≥18 years of age at the time of diagnosis * Patients intended for platinum-based chemotherapy treatment * Patients capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol * Patients consent to provide archival tumor tissue sample Patients are ineligible to be included in the study, if any of the exclusion criteria are met: * Non-epithelial ovarian cancer, borderline tumors, or mucinous histology * Patients with FIGO stage I-II, BRCAwt ovarian cancer

Primary outcome measure(s)

  • Endpoint OP1 — 60 months
    Frequency of surgical resection

Trial sites (1)

FacilityCityRegionStatus
Rigshospitalet København Ø Region Sjælland Recruiting

More Nordic Society of Gynaecological Oncology - Clinical Trials Unit trials in Denmark

Olaparib, Durvalumab and UV1 in Relapsed Ovarian Cancer Active, not recruiting

Other trials for the same condition

Normethermic Intraperitoneal Chemotherapy - a Novel Concept for Local Treatment of the Elderly and Fragile Women With Advanced Ovarian Cancer? Recruiting
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20) Recruiting
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing Active, not recruiting
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Active, not recruiting
Olaparib, Durvalumab and UV1 in Relapsed Ovarian Cancer Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05574673 on ClinicalTrials.gov ↗ ← All trials in Denmark